Fundraising Fox
Faeth Therapeutics
NASDAQ: FTHAustin, US · Delaware corporation · 42 employees on LinkedIn · 14 known investors
Find your way into Faeth Therapeutics
Sign up to see every warm intro you have to Faeth Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Faeth Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.
Founders & leadership
Board
Investors · 14
How we know: the VCSheet dataset · Not right? Tell us
How we know: AgFunder's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Cota Capital's portfolio page · Not right? Tell us
How we know: Future Ventures's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us
How we know: KdT Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: S2G Investments's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$24.4M disclosed across 1 of 2 rounds · 1900–2025
▶$24.4MraisedJan 2026 · 35 investors · BiotechnologyRule 506(b)
- Jayson DallasDirector
- Anand ParikhExecutive Officer, Director, Promoter
- Alex MorganDirector
- Robert GouldDirector
- Stephen HahnDirector
- Oliver MaddocksExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $24.4M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Faeth Therapeutics went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Faeth Therapeutics.
Frequently asked questions
- What does Faeth Therapeutics do?
- Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.
- Who founded Faeth Therapeutics?
- Faeth Therapeutics was founded by Anand Parikh, Oliver Maddocks.
- Who are Faeth Therapeutics's investors?
- Faeth Therapeutics's investors include Able Partners, AgFunder, Atacama Ventures, Cota Capital, Future Ventures, iSelect Fund, KdT Ventures, S2G Investments and 6 more.
- How much funding has Faeth Therapeutics raised?
- Faeth Therapeutics has disclosed $24.4M raised across 1 of its 2 known rounds.
- Where is Faeth Therapeutics headquartered?
- Faeth Therapeutics is headquartered in Austin, US.